US 2024/0200151 A1 · METAGENOMIC NEXT-GENERATION SEQUENCING OF MICROBIAL CELL-FREE NUCLEIC ACIDS IN SUBJECTS WITH LYME DISEASE

Abstract

What is disclosed herein is a method of detecting and treating Lyme disease, particularly Lyme arthritis. The method includes metagenomic next-generation sequencing (mNGS) of plasma microbial cell-free DNA (mcfDNA) to detect and quantify Borrelia spp. in the circulation. Also disclosed is a method of treating Lyme arthritis by treating the patient with an anti-microbial treatment until Borrelia mcfDNA is lowered to below detectable levels, such as less than 1 molecule per microliter of plasma.

Claims29

Dependent claims

A method of treating a Borrelia spp. infection in a subject that has received a diagnosis of the Borrelia spp. infection, wherein the diagnosis of the Borrelia spp. infection was based at least in part on [[the]]a method comprising:

a. collecting one or more blood samples from the subject at a time when the subject does not have an erythema migrans (EM) rash and wherein the one or more blood samples comprise microbial cell-free nucleic acids (mcfNA);
b. detecting mcfNA from Borrelia spp. in the one or more blood samples;
and
c. diagnosing the subject with the Borrelia spp. infection based at least in part on the detecting the mcfNA from the Borrelia spp.

1 more element

Dependencies are inferred from the claim text.

Metagenomic next-generation sequencing of microbial cell-free nucleic acids in subjects with lyme disease

Life of this patent

Metagenomic next-generation sequencing of microbial cell-free nucleic acids in subjects with lyme disease

Life of this patent

Abstract

Claims29